Article
Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib.
Cancer medicine - 1 Oct 2022
Shibaki Ryota, Ozawa Yuichi, Noguchi Susumu, Murakami Yusuke, Takase Eri, Azuma Yuichiro, Maebeya Masaru, Sugimoto Takeya, Hayata Atsushi, Hayakawa Takahiro, Tamaki Shinya, Nakanishi Masanori, Teraoka Shunsuke, Akamatsu Hiroaki
Abstract excerpt
BACKGROUND: First-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) sometimes causes lung injury, thereby affecting survival. Although pre-existing interstitial lung abnormal shadow (pre-ILS) increases the risk of lung injury by EGFR-TKIs, its impact on osimertinib, a third-generation EGFR-TKI, remains unknown. PATIENTS AND METHODS: This retrospective cohort study consecutively...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.